Open AccessSafety and medical cost effectiveness of preventive treatment of children with latent tuberculosis infection
Author(s) -
О. Д. Баронова,
Valentina Aksenova,
Н. И. Клевно,
В. С. Одинец,
О. В. Пилипенко
Publication year - 2020
Publication title -
tuberkulez i bolezni lëgkih/tuberkulëz i bolezni lëgkih
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.226
H-Index - 12
eISSN - 2542-1506
pISSN - 2075-1230
DOI - 10.21292/2075-1230-2020-98-9-25-31
Subject(s) - pyrazinamide , medicine , rifapentine , isoniazid , latent tuberculosis , ethambutol , regimen , rifampicin , tuberculosis , pediatrics , prospective cohort study , adverse effect , surgery , mycobacterium tuberculosis , pathology
The objective: to assess the safety and medical cost effectiveness of different LTBI treatment regimens in children and adolescents. Subjects and methods . 205 children in the age from 6 to 17 years old with latent tuberculosis infection were included in the study: The main (prospective) group included 31 children who were treated with isoniazid and rifapentine (HRpt). The comparison (retrospective) group included 174 pediatric patients: 128 patients received the regimen consisting of isoniazid and pyrazinamide (HZ), 14 patients received isoniazid and rifampicin (HR), and 32 patients received isoniazid and ethambutol (HE). Results . When using the HRpt regimen, the treatment was well tolerated; adverse events (eosinophilia) were documented in 6.5% of children. The medications were taken once a week and it allowed reducing the frequency of treatment interruptions for non-medical reasons. The overall cost per patient was lower with the HRpt regimen than with the other three LTBI treatment regimens.